IP Library Granted Patent US 12,419,971
Granted Patent B2
US 12,419,971 · App. 16/727,647 · Granted Sep 23, 2025

Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein

Inventors: Pierre Fafournoux (Auriers, FR); Jacques Mallet (Paris, FR)
Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION L'ENVIRONNEMENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; SORBONNE UNIVERSITE; ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
A61K48/0058A01K67/0275A61K35/00A61K45/06C07K14/70575C12Q1/6897A01K2207/25A01K2217/30A01K2227/105A01K2267/0331A01K2267/0393C12N2740/16043C12N2830/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,971
App. No.
16/727,647
Granted
Sep 23, 2025
Kind
B2
Abstract

A nucleic acid for the controlled expression of a nucleic acid encoding a pro-apoptotic protein in an individual, including: a regulatory polynucleotide including a minimal promoter and at least one AARE (amino acid response element) nucleic acid, the regulatory polynucleotide being activated in an individual upon consumption of a diet deficient in at least one essential amino acid; and a nucleic acid encoding a pro-apoptotic protein, which is placed under the control of the regulatory polynucleotide.

Claims (14)

1. A method for eliminating infused cells which contain a nucleic acid comprising:

a regulatory polynucleotide comprising a minimal promoter and at least one AARE (amino acid response element) nucleic acid, the regulatory polynucleotide being activated in a human individual upon consumption of a diet deficient in at least one essential amino acid; and

a suicide safety gene selected from the group consisting of: BCL2 modifying factor, Apoptosis inducer NBK, Apoptotic protease-activating factor 1 (APAF1, CED4), BAX, Endophilin B1, FADD, CRADD, FAS, Modulator of apoptosis 1, SMAC, Endonuclease G, HRK, Serine protease HTRA2, p53, NOXA, RIPK1, Bcl2 binding component 3, PMAIP1, Tumor necrosis factor receptor superfamily member 10A Precursor (Death receptor 4), caspase 1, caspase 3, caspase 7, caspase 8, and caspase 9, the product of which is associated with the killing of cells, said suicide safety gene being placed under the control of the regulatory polynucleotide, the method comprising:

a) administering the infused cells to a human individual in need of cancer treatment or regenerative medicine, and then

b) eliminating the infused cells by inducing programmed cellular death into at least one of the infused cells by submitting the human individual to a diet deficient in at least one essential amino acid.

2. The method according to claim 1 , wherein in the nucleic acid, the amino acid response element (AARE) nucleic acid is a nucleic acid of a sequence selected from the group consisting of SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4 and SEQ ID No: 5.

3. The method according to claim 1 , wherein in the nucleic acid, the regulatory polynucleotide comprises at least two AARE nucleic acids.

4. The method according to claim 1 , wherein the nucleic acid comprises a suicide gene encoding a protein performing a suicide task, which protein is selected from the group consisting of caspase 1, caspase 3, caspase 7, caspase 8 and caspase 9.

5. The method according to claim 4 , wherein the protein performing a suicide task is caspase 9.

6. The method according to claim 1 , wherein the nucleic acid is comprised in a nucleic acid vector for the controlled expression of a suicide safety gene.

7. The method according to claim 1 , wherein the nucleic acid, or a nucleic acid vector comprising the nucleic acid, is comprised in a delivery particle.

8. The method according to claim 7 , wherein the delivery particle comprises at its surface one or more ligands suitable for binding to a target receptor exposed at the membrane of a targeted cell.

9. The method according to claim 1 , wherein the infused cells are selected from the group consisting of CAR T-cells and stem cells.

10. The method according to claim 1 , wherein the infused cells are stem cells selected from the group consisting of hematopoietic stem cells and iPS cells.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE 4TH ASIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 061425 FRAME: 0734. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 25, 2022
From: MALLET, JACQUES
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; SORBONNE UNIVERSITE; ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
Reel/Frame 061769/0735 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2022
From: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT; SORBONNE UNIVERSITE; ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
Reel/Frame 061425/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2022
From: MALLET, JACQUES
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; SORBONNE UNIVERSITE; ASSISTANCE PUBLIQUE - HÔPITAUX PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
Reel/Frame 061425/0734 →
CHANGE OF NAME Recorded Jun 5, 2020
From: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
To: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Reel/Frame 052858/0238 →
Continuity (3)
Division 16306832
Provisional Application 62345162 · Jun 3, 2016
Related Publication 20200188533A1 · Jun 18, 2020
References Cited (15)
US 20140322184A1 · Farfournoux · 2014 [cited by examiner]
Marin et al. (Human Gene Therapy Methods 23:376-386 (Dec. 2012)). (Year: 2012). [cited by examiner]
Waehler et al. (Nature Reviews Genetics vol. 8, pp. 573-587 (2007)) (Year: 2007). [cited by examiner]
Greco et al. (Frontiers in Pharmacology. May 2015; 6(95): 1-13) (Year: 2015). [cited by examiner]
Traversari et al., “The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies”. Blood. Jun… [cited by examiner]
Jones et al. “Improving the safety of cell therapy products by suicide gene transfer”. Front Pharmacol. Nov. 27, 2014; 5:254. (Year: 2014). [cited by examiner]
May 14, 2021 U.S Office Action issued U.S. Appl. No. 16/306,832. [cited by applicant]
Waxman et al. (Cancer Research 63, 8563-8572, Dec. 15, 2003]). (Year: 2003). [cited by applicant]
Oct. 7, 2021 Office Action issued in U.S. Appl. No. 16/306,832. [cited by applicant]
Chaveroux et al., “In vivo imaging of the spatiotemporal activity of the elF2a-ATF4 signaling pathway: Insights into stress and related disorders,” Stress Signaling, Apr. 23, 2015, vol. 8, No. 374, pp. 1-11. [cited by applicant]
Kilberg et al., “ATF4-dependent transcription mediates signaling of amino acid limitation,” Trends in Endocrinology and Metabolism, 2009, vol. 20, No. 9, ,pp. 436-443. [cited by applicant]
Averous et al., “Amino acid deprivation regulates the stress-inducible gene p8 via the GCN2/ATF4 pathway,” Biochemical and Biophysical Research Communications, 2011, vol. 413, pp. 24-29. [cited by applicant]
Bruhat et al., “Amino Acids Control Mammalian Gene Transcription: Activating Transcription Factor 2 is Essential for the Amino Acid Responsiveness of the CHOP Promoter,” Mol. Cell. Biol., Oct. 2000, vol. 20, No. 19, pp.… [cited by applicant]
Bruhat et al., “Amino acids as regulators of gene expression in mammals: Molecular mechanisms,” BioFactors, pp. 249-257. [cited by applicant]
Aug. 22, 2017 International Search Report issued in International Patent Application No. PCT/EP2017/063422. [cited by applicant]